We report the surprising finding that common germline polymorphisms of APOE, present in approximately 39% of Caucasians, predict survival outcomes in human melanoma. Analysis of The Cancer Genome Atlas revealed that carriers of the APOE2 variant experienced shorter survival relative to APOE3 homozygotes, while APOE4 variant carriers exhibited increased survival. Consistent with this, melanoma growth in human APOE knock-in mice followed the order of APOE2 > APOE3 > APOE4, revealing causal regulation of progression by APOE variants. Mechanistically, recombinant ApoE protein variants differentially suppressed melanoma cell invasion and endothelial recruitment phenotypes. Moreover, tumors in APOE4 mice exhibited greater immune cell infiltration and activation relative to tumors of APOE2 mice. These findings support the notion that human germline genetic makeup can impact the trajectory of a future malignancy.
participants in the TCGA-SKCM study ( Fig. 1b) (15) . In comparison to a control group with similar age and ethnic composition (16) , homozygotes for the most common APOE3 variant (i.e., non-E2/E4 carriers) were modestly overrepresented in the TCGA-SKCM cohort, indicating that neither APOE2 nor APOE4 carrier status predisposed for increased melanoma incidence (Fig. 1c) . Strikingly, however, APOE carrier status was significantly associated with survival (median survival of 2.4, 5.2, and 10.1 years for E2 carriers, E3;E3 homozygotes, and E4 carriers, respectively; p = 0.0038, log-rank test; Fig. 1d ). Cox proportional hazard regression analysis revealed an increased hazard ratio for E2 carriers versus E3;E3 homozygotes (HR = 2.08, p = 0.01) and versus E4 carriers (HR = 3.69, p < 0.001). There were no significant differences in potentially confounding characteristics such as gender, age, tumor stage, Clark level, Breslow depth, and mutational or transcriptomic subtype between APOE carrier groups at the time of diagnosis (Extended Data Fig. 1a-g E3;E3, E3;E4, and E4;E4, respectively; p = 0.017, log-rank test) ( Fig. 1f and Extended Data Fig. 1h ). Thus, germline genetic variants of APOE genotype were significantly associated with survival in patients with advanced localized melanoma.
In order to assess whether APOE genotype merely correlated with or was causally involved in altering melanoma outcome, we used mice in which the endogenous murine Apoe locus is replaced with one of the three human APOE variants (11, 17, 18) . Using the YUMM1.7 murine melanoma model, we observed significantly slower tumor progression in E4;E4 and faster tumor progression in E2;E2 mice relative to E3;E3 mice, consistent with APOE genotype causally impacting melanoma progression in a manner analogous to the observed clinical association ( Fig. 2a ). In order to assess the impact of APOE genotype on metastatic progression of melanoma we used the aggressive B16F10 mouse melanoma model which exhibits efficient lung colonization upon intravenous injection. APOE2 mice exhibited a significantly enhanced metastatic progression rate relative to APOE3 and APOE4 mice ( Fig. 2b ).
Our findings in primary tumor growth and metastatic colonization models of melanoma revealed enhanced progression in APOE2 mice relative to APOE3 and APOE4 mice, consistent with the clinical association observations. The differential impact of APOE3 and APOE4 on progression, however, was only observed in the aforementioned primary tumor growth assay but not in the metastatic colonization assays. To confirm that APOE3 and APOE4 differentially impact melanoma progression, we employed a second independent model of melanoma progression. We hypothesized that a genetically induced model of melanomagenesis might provide better resolution and sensitivity for capturing a potential difference between these variants.
To this end, we crossed APOE3 and APOE4 mice to Tyr::CreER;Braf V600E/+ ;Pten lox/lox mice, in which melanoma formation can be initiated through Tamoxifen-induced and Cre-mediated excision of Pten in melanocytes (19) (Fig. 3a ). This five gene loci and one transgene compound mutant expressed ApoE variants in both the tumor and host compartments. Mice with the E4;E4 genotype exhibited reduced melanoma tumor burden in comparison to E3;E3 mice, consistent with our results in the transplantable melanoma tumor progression model (Fig. 3b ). These findings reveal that human APOE alleles differentially regulated progression in murine melanoma models, consistent with the clinical association data described above.
ApoE exerts pleiotropic anti-tumor effects by suppressing melanoma cell invasion and endothelial recruitment (2) . We thus assessed whether ApoE variants differentially affect these phenotypes.
Recombinant ApoE3 and ApoE4 proteins were more efficient than ApoE2 in suppressing Matrigel invasion of B16F10 melanoma cells depleted of endogenous ApoE (Fig. 4a ). ApoE3 and ApoE4 were also more potent than ApoE2 in suppressing endothelial recruitment by highly metastatic human melanoma MeWo-LM2 cells (Fig. 4b ). These findings reveal that the ApoE2 variant, which confers worse prognosis in humans and enhanced melanoma progression in mice, is less effective at suppressing multiple cancer progression phenotypes. increased Granzyme B and Interferon-expression in NK, CD8+ and CD4+ T cells ( Fig. 4f-h) . These findings suggest that the differential impact of ApoE variants on melanoma progression likely results from alterations in multiple cell autonomous and non-cell autonomous phenotypes that collectively contribute to melanoma progression.
In summary, we show that highly prevalent variants of APOE exhibit differential effects on melanoma progression in mice and humans. These effects at the organismal level are accompanied by differential effects of ApoE variant proteins on cellular phenotypes affecting melanoma progression, including invasion, endothelial recruitment, and immune cell infiltration and activation. Our findings reveal ApoE2 to be hypomorphic and ApoE4 to be hypermorphic in suppressing cancer progression phenotypes. What is the biochemical basis for this difference? Our past work has shown that ApoE proteins mediate suppressive effects on melanoma cell invasion, endothelial recruitment, and G-MDSC survival by acting on ApoE receptors LRP1 and LRP8 (1, 2) . ApoE variants have been previously shown to exhibit differential binding affinities to the ApoE receptor LDLR (E2 << E3 < E4) (5) . Differential binding or signaling by distinct ApoE variants has also been reported for additional ApoE receptors such as LRP1 and LRP8 (6, 7, 20) . Thus, the differential phenotypic effects of these variants on suppressing melanoma progression and prometastatic cellular phenotypes is consistent with their established receptor binding capacities for ApoE receptors. Our findings reveal the surprising observation that the APOE4 variant, which is associated with increased risk of Alzheimer's disease and atherosclerosis, is protective against melanoma progression.
These findings have important clinical implications as they may help to identify patients at high risk for metastatic progression for treatment with systemic therapy. More generally, our findings reveal that germline genetic variants can impact progression of a common human cancer and raise the possibility of the existence of additional common gene variants that predict and govern progression outcomes in other common malignancies.
Methods

Impact of APOE genotype on survival in human melanoma in the TCGA-SKCM cohort
To assess APOE genotypes of patients with melanoma, we downloaded aligned whole exome sequencing BAM files sliced for the genomic coordinates chr19:44904748-44910394 (GRCh38) from the TCGA-SKCM project using the Genomic Data Commons API (15). We called APOE variants using the samtools/bcftools package (21) , providing allele frequencies for chr19:44908684 (rs429358) and chr19:44908822 (rs7412) as determined in the Atherosclerosis Risk in Communities (ARIC) study (16) as a prior distribution. Normal tissue samples (either blood, solid tissue, or buccal cells) were available for 470 patients. No genotype could be determined in 10 patients. Additionally, patients that exhibited the E2;E4 genotype (n = 5) were excluded from analyses except for genotype frequency assessment. APOE genotype abundance in the normal population was based on the assessment of Caucasian patients in the ARIC study (16) .
Clinical data including survival times and clinical response were used as recently curated (22) . The R package 'TCGAbiolinks' was used to add clinical data for Breslow depth and Clark level (23) . To assess the impact of APOE genotypes on survival, Kaplan-Meier survival analysis was performed, and statistical significance was assessed with the log-rank test using the 'survival' and 'survminer' packages (24, 25) .
Hazard ratios were calculated according to a Cox proportional hazards regression model using the 'survival' R package (24) . For visualization purposes, survival data were truncated at 16 years, after which there were only individuals in the E3;E3 group remaining. All analyses were performed using R v3.5 (The R Foundation for Statistical Computing) and RStudio v1.1.3.
Animal studies
All animal experiments were conducted in accordance with a protocol approved by the Institutional Animal Care and Use Committee at The Rockefeller University. Human APOE2 (strain #1547), APOE3 (#1548) and APOE4 (#1549) targeted replacement (knock-in) mice were obtained from Taconic Biosciences.
Tyr::CreER;Braf V600E/+ ;Pten lox/lox mice (19) were obtained from Jackson laboratories (#013590).
Tumor growth studies
To assess the impact of APOE genotype on the growth of syngeneic melanoma we subcutaneously injected 1 × 10 5 (YUMM1.7) cells into the flank of 7-10-week-old and sex-matched human APOE targeted replacement mice. Cells were injected in a total volume of 100 µL and YUMM1.7 cells were mixed 1:1 with growth factor reduced Matrigel (356231, Corning) before injection. Tumor size was measured on the indicated days using digital calipers and calculating tumor volume as (small diameter) 2 ´ (large diameter) ´ P / 6.
Tail-vein metastasis assays
For tail-vein assays, B16F10 cells stably expressing a retroviral construct encoding luciferase were used in order to assess cancer progression by bioluminescence imaging as described previously (3, 26) . To assess whether APOE genotype impacts metastatic progression, 1 × 10 5 cells resuspended in 100 µL of PBS were injected into the tail vein of 6-8-week-old male human APOE knock-in mice. Bioluminescence imaging was performed approximately twice a week and the signal was normalized to the signal obtained on day 0.
Genetically initiated model of melanoma progression
Human APOE targeted replacement (knock-in) mice were crossed with Tyr::CreER;Braf V600E/+ ;Pten lox/lox mice. To induce melanoma, 6-7-week-old female mice were injected intraperitoneally with 1 mg of Tamoxifen (T5648, Sigma-Aldrich) on three consecutive days. Tamoxifen solution was prepared by dissolving Tamoxifen powder in 100 % ethanol at 50°C for five minutes and subsequent tenfold dilution in peanut oil to yield a 10 mg/mL working solution. To assess melanoma burden, dorsal skin samples stretching from ears to hips were harvested on day 35 after induction, depilated with commercial depilation cream (Nair), washed with water and fixed in 4% PFA. Skins were then scanned and the percentage of pigmented melanoma lesion area was quantified using Cellprofiler v3 (27) .
Cell lines
Mouse B16F10 melanoma cells and human umbilical vein endothelial cells (HUVEC) were obtained from the American Tissue Type Collection and cultured according to the supplier's conditions. B16F10 cells transduced with a retroviral construct to express luciferase (26) and shRNA targeting murine Apoe (shRNA clone TRCN0000011799; B16F10-TR-shApoe) were described previously (3) . YUMM1.7 cells, originally derived from a Braf V600E/+ ;Pten -/-;Cdkn2a -/-mouse melanoma, were generously provided by Marcus Bosenberg (28) . MeWo melanoma cells were originally obtained from the American Tissue Type Collection.
The highly metastatic MeWo-LM2 subclone was described previously (2) . B16F10 and MeWo cells were (29) .
Mouse genotyping
Genotyping of Tyr::CreER;Braf V600E/+ ;Pten lox/lox mice was performed as recommended by the Jackson Laboratory. Genotyping to distinguish between mouse and human APOE was performed using standard PCR with independent reactions for mouse and human APOE (PCR product lengths of 200 bp and approximately 600 bp, respectively). In order to distinguish between human APOE alleles, we used PCRbased restriction fragment length polymorphism genotyping (30) . In brief, a 244 bp fragment of APOE was amplified using standard PCR and digested with HhaI (R0139S, New England Biolabs), and allele-specific products were resolved on a 15% polyacrylamide gel. The following primers were used for the indicated PCR reactions: Pten forward: 5' -CAA GCA CTC TGC GAA CTG AG -3'
Isolation of tumor-infiltrating leukocytes
To isolate tumor-infiltrating leukocytes, YUMM1.7 tumors were resected on day 21 after injection and thoroughly minced on ice using scalpels. Tumor pieces were incubated in HBSS2+ (HBSS with Calcium and Magnesium (24020, Gibco) supplemented with 2% FBS, 1 mM sodium pyruvate (11360, Gibco), 25 mM HEPES (15630, Gibco), 500 U/mL Collagenase IV (LS004188, Worthington), 100 U/mL Collagenase I (LS004196, Worthington), and 0.2 mg/mL DNAse I (10104159001, Roche)) for 30 minutes at 37ºC on an orbital shaker (80 rpm). After thorough trituration the mixture was passed through a 70 µm strainer and diluted with HBSS2-(HBSS without Calcium and Magnesium (14170, Gibco), 2% FBS, 1 mM sodium pyruvate, and 25 mM HEPES). After centrifugation the cell pellet was resuspended in a 35 % Percoll solution (170891, GE Healthcare) and a phase of 70 % Percoll was underlaid using a glass Pasteur pipette.
The resulting gradient was centrifuged at 800 ´ g for 20 minutes at room temperature without brakes. After removal of the red blood cell-containing pellet on the bottom and excess buffer containing cellular debris on the top, the cell population at the Percoll interphase enriched for tumor-infiltrating leukocytes was washed twice with HBSS2-.
Flow cytometry
Unless otherwise mentioned all steps were performed on ice and under protection from light. For intracellular staining of cytokines, cells were incubated with 500 ng/mL ionomycin (I0634, Sigma), 100 ng/mL Phorbol 12-myristate 13-acetate (P8139, Sigma), and 10 µg/mL Brefeldin A (B7651, Sigma) for 3-4 hours at 37ºC prior to surface labelling and live/dead staining as described above. Cells were then incubated in fixation/permeabilization buffer (00-5523, eBioscience) for 30 minutes on ice, washed with permeabilization buffer (00-5523, eBioscience), and incubated with antibodies diluted in permeabilization buffer for 20 minutes on ice. Finally, cells were washed with permeabilization buffer and subsequently with staining buffer.
Antibodies
The following anti-mouse fluorophore-conjugated antibodies were used for flow cytometry: CD45 (clone 30- 
Matrigel invasion assay
The assay was performed similarly to as described previously (2) . B16F10-TR-shApoe mouse melanoma cells were serum starved overnight in DMEM supplemented with 0.2 % FBS. Prior to starting the assay, four Matrigel invasion chambers per condition (Corning, 354480) were equilibrated at 37ºC with 500 µL of 0.2% FBS DMEM in the top and bottom chambers. After 30 minutes, the starvation media in the top chamber was removed and replaced with 500 µL of starvation media containing 1 × 10 5 melanoma cells and either 10 µg/mL of HEK293-produced recombinant ApoE2, E3, or E4 (Tonbo Biosciences 21-9195, 21-9189, and 21-9190), or an equimolar concentrations of BSA (20 µg/mL; Sigma A3059). Chambers were then kept at 37ºC for 24 hours to allow for invasion. Subsequently, the chambers were washed with 1× PBS, the tops were scraped with cotton swabs to remove residual non-invading cells, and the inserts were fixed in 4% paraformaldehyde for 20 minutes. After washing again with PBS, inserts were stained with DAPI (Roche, 10236276001) for 5 minutes, cut out, and then mounted bottom-up on slides with ProLong Gold Antifade Mountant (Invitrogen, P36930). Four representative images per insert were taken using a Zeiss Axiovert 40 CFL fluorescence microscope at 10× magnification, and the number of invaded cells was quantified.
Endothelial recruitment assay
Human umbilical endothelial vein cells (HUVEC) were serum-starved overnight in EGM-2 media (Lonza, CC-3162) containing 0.2% FBS. Concurrently, 5 × 10 4 highly metastatic MeWo-LM2 human melanoma cells were plated in a 24-well plate in DMEM supplemented with 10% FBS. On the day of the assay, the medium was replaced with EGM-2 starvation medium, and Mewo-LM2 cells were allowed to enrich the media for 6-8 hours at 37ºC. Subsequently, BSA (20 ug/mL; Sigma, A3059) or ApoE2, E3, or E4 (10ug/ml; Tonbo Biosciences 21-9195, 21-9189, and 21-9190) were added to the media, and 3.0 µm PET membrane inserts (Falcon, 353492) were placed in the wells. HUVEC cells were trypsinized, resuspended, and seeded equally into the top chambers. The cells were allowed to migrate for 16 to 18 hours, after which the inserts were mounted and analyzed as described for the invasion assay above.
Statistical analysis
Unless otherwise noted all data are expressed as mean ± standard error of the mean. Groups were compared using tests for significance as indicated in the figure legends and the text. A significant difference was concluded at P < 0.05. Throughout all figures: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Unless indicated otherwise all box plots show median, first and third quartiles, and whiskers represent minimum and maximum.
Data availability
accession numbers: TCGA-SKCM dbGaP accession phs000178.v10.p8. Experimental data will be available from the corresponding author upon request. Fraction of patients (18) Extended Data Fig. 2 | Immunoprofiling of the tumor microenvironment in APOE2 versus APOE4 mice. a-b, Representative flow cytometry plots demonstrating the gating strategy to identify major myeloid (a) and lymphoid (b) cell subsets in the tumor microenvironment. c-d, Proportion of Ly6C+ (c) and dendritic cell (d) subsets in the immune microenvironment of YUMM1.7 tumors in APOE2 and APOE4 mice (two-tailed t-test). 
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